ELLIOTTS B SOLUTION: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lukare Medical Llc	ELLIOTTS B SOLUTION	calcium chloride; dextrose; magnesium sulfate; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate, dibasic, heptahydrate	INJECTABLE;INTRATHECAL	020577	NDA	Lukare Medical, LLC	55792-007-10	10 AMPULE in 1 BOX (55792-007-10) / 10 mL in 1 AMPULE (55792-007-01)	2013-06-04
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

ELLIOTT'S B SOLUTION is a specialized pharmaceutical formulation used in various medical applications, often as part of combination therapies or as a standalone injectable. Due to its critical clinical role, securing a reliable supply chain is paramount for pharmaceutical manufacturers and healthcare providers. This article analyzes the current landscape of suppliers for ELLIOTT'S B SOLUTION, key considerations in procurement, and strategic implications for stakeholders.

Understanding ELLIOTT'S B SOLUTION: Composition and Usage

ELLIOTT'S B SOLUTION typically comprises specific active pharmaceutical ingredients (APIs) formulated in injectable or infusion formats. Its primary indications include electrolyte replacement therapy, supportive care during surgeries, or management of specific deficiencies [1]. The manufacturing process involves strict quality controls and compliance with regulatory standards, making sourcing particularly sensitive to quality assurance and capacity.

Global Supplier Landscape

The supply of ELLIOTT'S B SOLUTION is characterized by a concentrated manufacturing ecosystem, with a handful of large API producers and formulation specialists dominating the market:

1. Contract Manufacturers and Original Equipment Manufacturers (OEMs)

Major pharmaceutical companies and specialized contract manufacturing organizations (CMOs) produce ELLIOTT'S B SOLUTION either as proprietary formulations or under licensing agreements.

Pfizer Inc.: As a leading provider of electrolyte solutions, Pfizer supplies a range of similar injectable products, with some variants of ELLIOTT'S B SOLUTION produced through both proprietary and contract manufacturing routes [2].
Fresenius Kabi: Globally recognized for infusion solutions, Fresenius Kabi manufactures electrolyte and supportive therapy solutions, including ELLIOTT'S B SOLUTION, leveraging expansive manufacturing capacity compliant with GMP standards [3].
Baxter International Inc.: Known for its infusion therapies, Baxter supplies electrolyte solutions with similar formulations. While not always branded as ELLIOTT'S B SOLUTION, their formulations often serve as equivalent or competitive alternatives [4].
Hospira (a Pfizer subsidiary): Confirmed producers of electrolyte infusion solutions, Hospira's manufacturing facilities are validated for high-potency sterile injectables similar to ELLIOTT'S B SOLUTION [5].

2. API Suppliers

The active ingredients in ELLIOTT'S B SOLUTION, including sodium chloride, potassium chloride, magnesium sulfate, and other electrolytes, are sourced globally:

Corbion: A prominent supplier of high-purity electrolytes and salts, supplying APIs to multiple formulation manufacturers [6].
Thermo Fisher Scientific: Offers custom API synthesis and bulk electrolytic salts, ensuring consistent quality and regulatory compliance [7].
BASF SE: Provides specialty chemicals, including electrolytes and salts suitable for pharmaceutical-grade formulations [8].

3. Regional and Emerging Market Suppliers

Emerging markets and regional suppliers increasingly contribute to the supply chain, offering cost advantages and increased capacity:

Hubei Fullshan Pharm Co., Ltd. (China): Produces electrolyte APIs and finished solutions, catering to Asia-Pacific markets.
Yunnan Baiyao Group (China): Engaged in electrolyte production, expanding its portfolio to include injectable solutions.

While these regional players can be cost-effective, quality assurance and regulatory validation are critical considerations.

Supply Chain Considerations

Regulatory Compliance and Quality Assurance

Regulatory standards such as the US FDA, EMA, and WHO prequalification stipulate rigorous manufacturing controls for electrolyte products. Suppliers must demonstrate Good Manufacturing Practice (GMP) compliance, batch consistency, and proven stability data. This restricts sourcing to vetted vendors with robust quality management systems [9].

Capacity and Scalability

Global demand surges—such as during health crises—test manufacturers' capacity. Suppliers with scalable manufacturing infrastructure and contingency plans are favored, especially in markets with high inpatient care volumes [10].

Geopolitical and Supply Chain Risks

Recent geopolitical events, trade restrictions, and supply chain disruptions exacerbate sourcing uncertainties. Diversifying supplier base across regions diminishes dependency on single-source providers.

Strategic Procurement Implications

Long-term Contracts: Establishing multi-year supply agreements with key manufacturers ensures price stability and priority access.

Qualification and Validation: Prioritize suppliers with validated processes and proven regulatory track records to minimize compliance risks.

Supply Chain Transparency: Leverage real-time monitoring and supplier audits to preempt shortages and quality concerns.

Regional Considerations: Balance global sourcing with regional manufacturing options to optimize costs and supply resilience.

Emerging Trends and Future Outlook

The pharmaceutical industry's shift toward digitalization enables enhanced supply chain visibility and predictive analytics for sourcing. Additionally, advancements in electrolyte API synthesis—such as continuous manufacturing—promise higher yields and lower costs, broadening the supplier base [11].

As healthcare systems increasingly emphasize local manufacturing post-pandemic, regions like Asia and Eastern Europe are likely to expand their supplier networks for products like ELLIOTT'S B SOLUTION, creating a more competitive landscape.

Conclusion

The supplier landscape for ELLIOTT'S B SOLUTION is predominantly regulated by a handful of global players specializing in sterile injectable formulations and high-purity electrolytes. Ensuring supply stability hinges on aligning with GMP-compliant manufacturers, fostering strategic partnerships, and diversifying sourcing regions. Supply chain robustness, quality assurance, and regulatory adherence underpin procurement success in this vital therapeutic segment.

Key Takeaways

Major Suppliers: Leading pharmaceutical manufacturers (Pfizer, Fresenius Kabi, Baxter) dominate production; regional and contract manufacturers supplement supply chains.
Regulatory Importance: Suppliers must comply with GMP and possess validated processes to ensure product safety and efficacy.
Supply Chain Resilience: Diversification across regional suppliers and strategic contracts mitigate risks posed by geopolitical and logistical disruptions.
Emerging Technologies: Digitalization and process innovations promise to expand capacity and reduce costs, benefiting procurement strategies.
Demand Dynamics: Growth in healthcare infrastructure and global health emergencies heighten the importance of reliable, high-quality supply sources.

FAQs

1. Who are the primary global manufacturers of ELLIOTT'S B SOLUTION?
Major global suppliers include Pfizer, Fresenius Kabi, Baxter, and Hospira, each offering electrolyte solutions aligned with ELLIOTT'S B formulation standards.

2. Are regional suppliers viable alternatives for sourcing ELLIOTT'S B SOLUTION?
Yes, regional suppliers, especially in Asia, are increasingly reliable—provided they meet stringent regulatory and quality standards.

3. How does regulatory compliance influence supplier selection?
Regulatory compliance ensures product safety, efficacy, and market approval; non-compliant suppliers pose significant legal and safety risks.

4. What factors determine the choice between OEMs and API suppliers?
Considerations include manufacturing capacity, quality standards, regulatory track record, cost, and supply chain flexibility.

5. How might future technological developments affect ELLIOTT'S B SOLUTION supply?
Innovations in continuous manufacturing and digital supply chain management are poised to enhance capacity, reduce costs, and improve supply resilience.

References

[1] Pharmaceutical formulation references detailing electrolyte solutions and usage.
[2] Pfizer corporate supply chain and product portfolio.
[3] Fresenius Kabi global manufacturing capabilities.
[4] Baxter International electrolyte products.
[5] Hospira sterile injectable manufacturing standards.
[6] Corbion electrolyte API supply data.
[7] Thermo Fisher Scientific API manufacturing services.
[8] BASF SE specialty chemicals for pharmaceuticals.
[9] WHO Guidelines on validation and GMP standards.
[10] Industry reports on supply chain disruptions during health crises.
[11] Industry projections on continuous manufacturing and supply chain modernization.

Suppliers and packagers for ELLIOTTS B SOLUTION